Finding. Haskins and colleagues compare a calpain-cleaved GFAP neoepitope with total GFAP in Veterans from traumatic brain injury through mild cognitive impairment to Alzheimer disease. After a plasma p-tau217 and amyloid-beta-42 gate, the neoepitope is the better CSF discriminator in the amyloid-committed subset.
Why the score is low here There is no mitochondrial measurement. The brief exists because the DOI was in the writer queue. Do not cite it for OXPHOS or mtDNA.
Score 46. Biomarker methods. Skip for organelle biology.
Free HTML is above. Bots pay for JSON at /api/v1/papers/10-64898-2026-09-01-26361845. Optional wallet tester: MetaMask ($0.005).
Source preprint
Proteoform-resolved neoGFAP ™ as a diagnostic and prognostic biomarker across the TBI–MCI–AD continuum in Veterans
10.64898/2026.09.01.26361845
Haskins WE, Wang KK, Cai G, Boukholda K, Elbayoumi E, Bajpai R, Jackson D, Tehas K, Radeker K, DeLizza A, Popper C, Kiendl M, Badrnya S, Miholits M, Jellbauer S, Kilbaugh T, Okumu F, Puccio A, Gardner RC, Manley G, Williamson JB, Waters AB, Li GG, Peskind ER.
